United Therapeutics (UTHR) Change in Accured Expenses (2009 - 2026)

United Therapeutics has disclosed Change in Accured Expenses across 18 years of filings, most recently posting -$12.7 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$12.7 million, down 388.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $87.8 million (up 129.84% YoY), and the FY2025 annual result was $97.9 million, up 129.27% from the prior year.
• Change in Accured Expenses came in at -$12.7 million for Q1 2026 at United Therapeutics, down from $23.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $46.1 million in Q2 2025 to a low of -$23.1 million in Q4 2023.
• The 5-year median for Change in Accured Expenses is $22.3 million (2022), against an average of $13.5 million.
• Across the five-year window, Change in Accured Expenses soared 228.89% in 2025 and sank 388.46% in 2026, its largest moves.
• United Therapeutics' Change in Accured Expenses stood at $9.1 million in 2022, then sank by 353.85% to -$23.1 million in 2023, then grew by 22.08% to -$18.0 million in 2024, then jumped by 228.89% to $23.2 million in 2025, then slumped by 154.74% to -$12.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$12.7 million (Q1 2026), $23.2 million (Q4 2025), and $31.2 million (Q3 2025), per Business Quant data.